TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22803423
Drug: PPI +
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI + DG group (Rabeprazole 20 mg once daily; DG 6 g thrice daily)
Study: 22803423
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group A (Rabeprazole Capsule 20 mg once daily)
Study: 22803423
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group B (Rabeprazole 20 mg once daily; Domperidone 10 mg thrice daily)
Study: 9204744
Drug: Conventional cholecystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cholecystectomy (CC)
Study: 31600487
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy alone
Study: 31600487
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy in combination with an immunomodulator
Study: 25990414
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptive (ethinylestradiol 20 μg/desogestrel 150 μg)
Study: 17907591
Drug: HFA-based budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HFA-based budesonide inhaler therapy
Study: 17907591
Drug: High-dosage (1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage (1,600 microg/day) HFA and CFC inhalers
Study: 9146848
Drug: Triazolam +
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam + Diltiazem (0.25 mg triazolam after 3-day treatment of 180 mg diltiazem)
Study: 2885203
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg with alcohol 32 ml
Study: 2885203
Drug: Acrivastine 8
Normalized name: acrivastine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine 8 mg with alcohol 32 ml
Study: 2885203
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg and 120 mg with alcohol 32 ml
Study: 16893273
Drug: Contingency Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency Management with Cognitive-Behavioral Therapy (CM+CBT)
Study: 16893273
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy alone (CBT)
Study: 20471542
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication order
Study: 20471542
Drug: Review of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Review of pain treatment plan
Study: 20471542
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in pain medication
Study: 20471542
Drug: Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of analgesic-induced side effects
Study: 20471542
Drug: Documentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Documentation of nonpharmacological therapies
Study: 12752032
Drug: Hallucination focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hallucination focused Integrative Treatment (HIT)
Study: 8604439
Drug: Predicted drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted drug efficacy
Study: 6218104
Drug: Mezlocillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (2 g intravenously before surgery and every eight hours until the fifth postoperative day)
Study: 17413103
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g fat/d (2.4 g fat/meal)
Study: 31044688
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to treatment
Study: 11172269
Drug: Pneumatic compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pneumatic compression therapy delivered after elective hip surgery
Study: 7842828
Drug: Teicoplanin plus
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin plus pefloxacine 10 mg/kg
Study: 22942727
Drug: ASA monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA monotherapy
Study: 31227453
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LIPUS treatment)
Study: 28304224
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg every 2 weeks or 420 mg monthly)
Study: 23880306
Drug: ART according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART according to national treatment eligibility guidelines (CD4 <350 cells/μL, WHO stage 3 or 4 disease, or multidrug/extensively drug-resistant tuberculosis)
Study: 21714857
Drug: Fenoldopam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (1 μg/kg/min continuous infusion during CPB)
Study: 9135945
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.05 IU/kg)
Study: 9135945
Drug: Insulin (correctly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (correctly informed)
Study: 9135945
Drug: Insulin (expectation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (expectation without knowledge)
Study: 3777587
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal (OAC) given in four doses at three-hour intervals starting three hours after SRT dosing (Group 3)
Study: 26689566
Drug: Alisertib (MLN8237)
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (MLN8237) 50 mg enteric-coated tablet under fed conditions
Study: 26689566
Drug: Alisertib (MLN8237)
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (MLN8237) 50 mg enteric-coated tablet under fasted conditions
Study: 26689566
Drug: Alisertib (MLN8237)
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (MLN8237) 50 mg enteric-coated tablet
Study: 10545552
Drug: iNO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNO at 20 ppm (after initial treatment with 0 ppm)
Study: 10545552
Drug: Low-dose iNO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iNO group (2 ppm)
Study: 22196566
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no massage therapy)
Study: 3724994
Drug: Electrical shocks
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical shocks administered to the right forearm at four intensities
Study: 21192262
Drug: Immunotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (specific agents not detailed)
Study: 21192262
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (specific agents not detailed)
Study: 12799847
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg and 100 mg
Study: 9085303
Drug: Tramadol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (higher doses)
Study: 3113538
Drug: Antibiotics given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics given to patients with proved bacteriuria (80 patients)
Study: 3113538
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (8 untreated patients with bacteriuria)
Study: 24643905
Drug: Odanacatib 50
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50 mg weekly for 2 years
Study: 19941679
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g butter with no Mg supplementation (fat-only meal)
Study: 15823831
Drug: tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibolone 2.5 mg
Study: 17085380
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol and 2 mg dienogest (E2/dienogest)
Study: 12660934
Drug: Control vector
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control vector (rabies virus glycoprotein G gene)
Study: 10823400
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (75 mg)
Study: 10823400
Drug: Tea (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea (75 mg caffeine)
Study: 6353831
Drug: FK 33-824
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 33-824 (0.5 mg im injection)
Study: 28420909
Drug: Intrauterine lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine lidocaine infusion
Study: 28420909
Drug: Control (4ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4ml intravenous normal saline)
Study: 23882146
Drug: 1,3-dimethylamylamine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,3-dimethylamylamine supplement
Study: 17046034
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g of creatine monohydrate, four times a day for 7 days)
Study: 76224
Drug: Five-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug regimen
Study: 31586999
Drug: Topical adapalene
Normalized name: adapalene Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with explicative leaflet (G1)
Study: 31586999
Drug: Topical adapalene
Normalized name: adapalene Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with SMS reminders (G2)
Study: 31586999
Drug: Topical adapalene
Normalized name: adapalene Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with standard instructions (G3)
Study: 25041252
Drug: Platform-switching implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switching implants placed 1 mm below bone level (test group)
Study: 25041252
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed at bone level (control group)
Study: 1388115
Drug: Nifedipine R
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine R (20-40 mg b.i.d.)
Study: 3890436
Drug: Metronidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1 g)
Study: 3890436
Drug: Doxycycline (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (0.2 g)
Study: 24682319
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg/week)
Study: 18073060
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (100 mg/d)
Study: 18073060
Drug: Lamivudine combined
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine combined with individualized low-dose HBIG
Study: 8129129
Drug: Conventional technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional technique with Bain system and tightly-fitting anaesthetic face-mask at 8 l.min-1
Study: 8129129
Drug: Hudson mask
Normalized name: MASK,TRACHEOSTOMY HUDSON #1075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hudson mask with Bain system at 8 l.min-1
Study: 2657954
Drug: General practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practice antenatal care (not specified dosage or duration)
Study: 2657954
Drug: Medication prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication prescribed during pregnancy
Study: 5307603
Drug: Heat-killed broth-grown
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed broth-grown sorbed dried vaccine (vaccine G-66)
Study: 5307603
Drug: Other types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other types of typhoid vaccines
Study: 5307603
Drug: Heat-killed broth-grown
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed broth-grown and acetone-killed agar-grown vaccines
Study: 26256065
Drug: Amlodipine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, 5 mg daily; Citalopram, 20 mg daily
Study: 26256065
Drug: Amlodipine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, 5 mg daily
Study: 15073471
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg once daily for 8 weeks
Study: 15073471
Drug: Eplerenone 100
Normalized name: eplerenone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 100 mg once daily for 8 weeks
Study: 15073471
Drug: Eplerenone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 200 mg once daily for 8 weeks
Study: 11932279
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (90 mg orally/d)
Study: 7640316
Drug: Small-volume hypocaloric
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-volume hypocaloric continuous feedings (1 ml/kg/h), beginning at 24 h of age
Study: 7640316
Drug: NPO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPO group (standard intravenous fluid and nutrition, nothing per OS)
Study: 2680286
Drug: co-dergocrine mesylate
Normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-dergocrine mesylate (3 mg daily intravenous infusion over 14 days)
Study: 187313
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with methotrexate, cyclophosphamide, procarbazine, and vincristine
Study: 187313
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with methotrexate, cyclophosphamide, procarbazine, and vincristine
Study: 187313
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment in patients with anaplastic small cell carcinoma
Study: 187313
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment in patients with anaplastic small cell carcinoma
Study: 187313
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment in patients with epidermoid carcinoma
Study: 187313
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment in patients with epidermoid carcinoma
Study: 187313
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with continued four-drug polychemotherapy
Study: 30710211
Drug: Enteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral administration of 4.5 g of arginine and 10 g of glutamine per day for 7 days prior to surgery
Study: 19086236
Drug: Alvimopan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan (both doses) in PCA group (n = 317)
Study: 19086236
Drug: Alvimopan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan (both doses) in non-PCA group (n = 318)
Study: 7853733
Drug: Acetylcholine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine infusion (15 eyes)
Study: 7853733
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS) infusion (control, 22 eyes)
Study: 3925488
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg methylphenidate
Study: 3925488
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg methylphenidate
Study: 3098
Drug: Cardioselective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta-blockers (practolol, H 87/07, metoprolol)
Study: 26140943
Drug: Reconstituted HDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted HDL (rHDL) 40 mg/kg
Study: 23268367
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tabalumab
Study: 23268367
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg tabalumab
Study: 29374382
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day zinc supplementation
Study: 19283648
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment as usual (TAU) without group sessions
Study: 17229079
Drug: Daclizumab, mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low‐dose CsA (target trough levels of 50‐100 ng/mL), weaned from month 4 and withdrawn by month 6
Study: 17229079
Drug: Daclizumab, MMF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab, MMF, CS and low‐dose CsA
Study: 17229079
Drug: Low‐dose CsA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose CsA group
Study: 17229079
Drug: Standard‐dose CsA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐dose CsA group
Study: 15820814
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A)
Study: 15820814
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus placebo tablets (group B)
Study: 15820814
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of a placebo solution plus placebo tablets (group C)
Study: 12212781
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mifepristone daily for 6 months
Study: 8564348
Drug: Disodium pamidronate
Normalized name: Disodium pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium pamidronate 60 mg
Study: 31277138
Drug: Celecoxib combined
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib combined with chemotherapy
Study: 31277138
Drug: Celecoxib combined
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib combined with chemotherapy (for COX-2 positive patients)
Study: 29276907
Drug: Sotalol (162.5±46.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (162.5±46.2 mg/day, n=24)
Study: 25115995
Drug: 5% Sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Sodium hypochlorite (NaOCl) used as a cleansing agent in pulpotomy procedures
Study: 1882896
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g granulate four times daily
Study: 6309542
Drug: Enprofylline (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (3.5 mg/kg)
Study: 6309542
Drug: Theophylline (9.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (9.5 mg/kg)
Study: 30634195
Drug: Low-volume bowel
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume bowel preparation (0.3L sodium picosulfate with magnesium citrate)
Study: 8956371
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase (L)
Study: 15750042
Drug: Bosentan (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily)
Study: 8686962
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage regimens
Study: 21422768
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (E-EPA) 1 g/day
Study: 16897990
Drug: S-1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80 mg/m2/day for 4 weeks followed by 2 weeks rest for a year)
Study: 16897990
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg/m2/day for 5 days followed by 2 days rest for a year)
Study: 15163474
Drug: Mg +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg + Zn (200 mg Mg and 30 mg Zn)
Study: 9159306
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker regimen (amlodipine)
Study: 9159306
Drug: Beta-blocker regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker regimen (atenolol)
Study: 27702823
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m2 every 3 weeks plus prednisone 10 mg/day (group CABA)
Study: 27702823
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m2 every 3 weeks with concomitant budesonide 9 mg daily during the first two treatment cycles (group BUD)
Study: 16306998
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/HCTZ 12.5 mg o.d.